Skip to main content
. 2021 Dec 14;22(24):13413. doi: 10.3390/ijms222413413

Figure 3.

Figure 3

Identification and validation of MEIS1 as a potential target gene of ICG−001. (A) Identification of candidate target genes of ICG−001. Stemness signature genes were filtered by overlapping four gene sets obtained from the transcriptomic data of tumors from CRC patients. Six candidate genes were upregulated in both recurrent and metastatic tumors and positively correlated with LEF1 and β-catenin (CTNNB1) expression. (B) RT−qPCR validation performed after ICG−001 treatment (2.5 μM, 72 h). The data are presented as a heatmap with fold changes and p−values. (C) RT−qPCR and Western blot analyses conducted 48 h after LEF1 or β-catenin knockdown. (D) Gene expression correlations between MEIS1 and LEF1/β-catenin. (E) MEIS1 transcript levels according to the degree of CRC progression (Dukes’ stage). (F) Kaplan–Meier survival analyses of CRC patients based on MEIS1 expression. (G) Western blot analyses comparing the MEIS1 protein level in multiple human cell lines. ** and *** indicate p < 0.01 and p < 0.001, respectively.